Edition:
India

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

234.01USD
11 Dec 2019
Change (% chg)

$0.00 (-0.00%)
Prev Close
$234.01
Open
$234.03
Day's High
$234.95
Day's Low
$233.03
Volume
898,760
Avg. Vol
1,051,079
52-wk High
$235.80
52-wk Low
$166.30

Latest Key Developments (Source: Significant Developments)

Amgen Data From Phase 3 Candor Study Combining Kyprolis To Be Presented During Late-Breaking Session At American Society Of Hematology Annual Meeting
Tuesday, 10 Dec 2019 

Dec 10 (Reuters) - Amgen Inc ::AMGEN DATA FROM PHASE 3 CANDOR STUDY COMBINING KYPROLIS® (CARFILZOMIB) AND DARZALEX® (DARATUMUMAB) TO BE PRESENTED DURING LATE-BREAKING SESSION AT AMERICAN SOCIETY OF HEMATOLOGY ANNUAL MEETING.AMGEN INC - TREATMENT WITH KYPROLIS, DEXAMETHASONE AND DARZALEX (KDD) RESULTED IN A SIGNIFICANT PROGRESSION-FREE SURVIVAL (PFS) BENEFIT.AMGEN- 37% REDUCTION IN RISK OF PROGRESSION OR DEATH COMPARED TO KYPROLIS AND DEXAMETHASONE (KD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA.AMGEN INC - PATIENTS TREATED WITH KDD ACHIEVED DEEPER RESPONSES THAN PATIENTS TREATED WITH KD ALONE.  Full Article

FDA Approves Amgen's Biosimilar To J&J's REMICADE
Friday, 6 Dec 2019 

Dec 6 (Reuters) - U.S. Food and Drug Administration::U.S. FDA APPROVES AMGEN'S AVSOLA (INFLIXIMAB-AXXQ) FOR INJECTION, FOR INTRAVENOUS USE; AVSOLA IS BIOSIMILAR TO REMICADE - LABEL ON FDA WEBSITE.  Full Article

Amgen Announces Data Being Presented At ASH 2019
Tuesday, 3 Dec 2019 

Dec 2 (Reuters) - Amgen Inc ::AMGEN ANNOUNCES DATA BEING PRESENTED AT ASH 2019.AMGEN-PHASE 3 CANDOR STUDY EVALUATING KYPROLIS® WITH DARZALEX® IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA PATIENTS ACCEPTED AS LATE-BREAKING ABSTRACT.AMGEN - DATA FROM AALL1331 EVALUATING BLINCYTO VERSUS CHEMOTHERAPY IN FIRST RELAPSE OF CHILDHOOD B-ALLWERE ACCEPTED AS A LATE-BREAKING ABSTRACT.  Full Article

Bristol-Myers Squibb Receives Clearance From U.S. FTC For Celgene Acquisition
Saturday, 16 Nov 2019 

Nov 15 (Reuters) - Bristol-Myers Squibb Co ::BRISTOL-MYERS SQUIBB RECEIVES CLEARANCE FROM U.S. FEDERAL TRADE COMMISSION FOR CELGENE ACQUISITION.BRISTOL-MYERS SQUIBB CO - TRANSACTION EXPECTED TO CLOSE ON NOVEMBER 20, 2019.BRISTOL-MYERS SQUIBB CO - FTC APPROVES AGREEMENT BETWEEN CELGENE AND AMGEN TO DIVEST OTEZLA.BRISTOL-MYERS SQUIBB CO - HAS NOW SATISFIED ALL REGULATORY APPROVALS FOR CELGENE ACQUISITION.BRISTOL-MYERS SQUIBB CO - BRISTOL-MYERS SQUIBB ALSO EXPECTS OTEZLA DIVESTITURE TO BE COMPLETED PROMPTLY FOLLOWING CLOSING OF MERGER.BRISTOL-MYERS SQUIBB - U.S. FEDERAL TRADE COMMISSION HAS ACCEPTED PROPOSED CONSENT ORDER IN CONNECTION WITH PENDING MERGER OF CO AND CELGENE.  Full Article

Revolution Medicines And Amgen Partner On Phase 1B Study To Evaluate Combination Of Rmc-4630 And Amg 510
Monday, 4 Nov 2019 

Nov 4 (Reuters) - Amgen Inc ::REVOLUTION MEDICINES AND AMGEN PARTNER ON PHASE 1B STUDY TO EVALUATE COMBINATION OF RMC-4630 AND AMG 510.REVOLUTION MEDICINES - AGREEMENT WITH AMGEN TO EVALUATE COMBINATION OF RMC-4630 AND AMG 510.REVOLUTION MEDICINES - AMGEN WILL CONDUCT PHASE 1B CLINICAL TRIAL EVALUATING SAFETY, TOLERABILITY, PHARMACOKINETICS, EFFICACY OF AMG 510 WITH RMC‑4630.  Full Article

AbbVie Says Doesn't View Any Change In Humira Pricing Going Into 2020
Friday, 1 Nov 2019 

Nov 1 (Reuters) - AbbVie Inc ::ABBVIE SAYS LAUNCH OF PSORIASIS DRUG SKYRIZI "IS GOING EXTREMELY WELL" AND COMMERCIAL ACCESS FOR THE DRUG IS AT MORE THAN 80% - CONF. CALL.ABBVIE SEES "VERY LITTLE CANNIBALIZATION" TO HUMIRA SALES FROM ITS NEW RHEUMATOID ARTHRITIS DURG RINVOQ - CONF. CALL.ABBVIE SAYS NEW RHEUMATOID ARTHRITIS DRUG RINVOQ HAS OUTPACED JOHNSON & JOHNSON'S REMICADE AND IS CLOSE TO OUTPACING AMGEN'S ENBREL - CONF. CALL.ABBVIE SAYS INTERNATIONAL BIOSIMILAR TRENDS AND DYNAMICS FOR HUMIRA RIVALS REMAIN CONSISTENT WITH EXPECTATIONS - CONF. CALL.ABBVIE SEES 2019 REVENUE GROWTH OF 2.5% ON OPERATIONAL BASIS - CONF. CALL.ABBVIE EXPECTS 2019 NON-GAAP TAX RATE JUST BELOW FULL YEAR RATE IN 2018- CONF. CALL.ABBVIE SAYS HAS NOTIFIED FTC OF INTENT TO DIVEST TWO ASSETS FOR ALLERGAN DEAL TO GO THROPUGH - CONF. CALL.ABBVIE SAYS SEEING "SEVERAL INTERESTED PARTIES" FOR ASSETS IT PLANS TO DIVEST FOR ITS ALLERGAN DEAL - CONF. CALL.ABBVIE DOESN'T VIEW ANY CHANGE IN HUMIRA PRICING GOING INTO 2020- CONF. CALL.ABBVIE CEO SAYS SUPPORTIVE OF SENATE FINANCE COMMITTEE PROPOSAL ON DRUG PRICING "WITH MODIFICATIONS" - CONF. CALL.ABBVIE EXPECTS ALLERGAN'S BOTOX TO CONTINUE TO PERFORM WELL DESPITE COMPETITION GOING FORWARD, NOTES IT IS DIFFICULT TO DEVELOP A BIOSIMILAR FOR THE PRODUCT - CONF. CALL.  Full Article

Amgen Qtrly GAAP EPS $3.27
Wednesday, 30 Oct 2019 

Oct 29 (Reuters) - Amgen Inc ::AMGEN - QTRLY GAAP EARNINGS PER SHARE $3.27; QTRLY ADJUSTED EARNINGS PER SHARE $3.66; QTRLY REVENUE $5.74 BILLION VERSUS ABOUT $5.9 BILLION.Q3 EARNINGS PER SHARE VIEW $3.53, REVENUE VIEW $5.63 BILLION -- REFINITIV IBES DATA.AMGEN - NOW SEES FY REVENUE $22.8 BILLION - $23.0 BILLION; SEES FY GAAP EPS $12.50 - $12.80; SEES FY ADJUSTED EPS $14.20 - $14.45.FY2019 EARNINGS PER SHARE VIEW $14.39, REVENUE VIEW $22.85 BILLION -- REFINITIV IBES DATA.AMGEN - EXPECTS OTEZLA ACQUISITION TO CLOSE BEFORE Q4-END.AMGEN - QTRLY TOTAL PRODUCT SALES DOWN 1%.  Full Article

Amgen's Chief Financial Officer David Meline To Retire
Wednesday, 23 Oct 2019 

Oct 22 (Reuters) - Amgen Inc ::DAVID MELINE, AMGEN'S CHIEF FINANCIAL OFFICER, TO RETIRE.PETER GRIFFITH TO ASSUME CFO ROLE IN 2020.MELINE WILL SERVE AS CFO THROUGH END OF 2019 AND REMAIN AT COMPANY INTO Q2 OF 2020.  Full Article

Amgen Sets Quarterly Dividend Of $1.45/Share
Wednesday, 23 Oct 2019 

Oct 22 (Reuters) - Amgen Inc ::SETS QUARTERLY DIVIDEND OF $1.45PER SHARE.  Full Article

Amgen Says Evenity® (Romosozumab) Receives Positive CHMP Opinion For Treatment Of Severe Osteoporosis In Postmenopausal Women At High Risk Of Fracture
Friday, 18 Oct 2019 

Oct 18 (Reuters) - Amgen Inc ::EVENITY® (ROMOSOZUMAB) RECEIVES POSITIVE CHMP OPINION FOR THE TREATMENT OF SEVERE OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN AT HIGH RISK OF FRACTURE.  Full Article

Photo

Bristol-Myers reports positive data on cancer treatment acquired in Celgene deal

Bristol-Myers Squibb Co on Saturday said that an experimental cancer therapy it acquired as part of its $74 billion deal for Celgene Corp produced positive results in a clinical trial.